Item 8.01. Other Events.

On August 17, 2009, Orthofix International N.V. (the "Company") announced that Kevin L. Unger has been appointed as President of the Company's spinal implants division.

As an inducement to Mr. Unger to enter into employment with the Company, Mr. Unger has been granted an initial award of stock options to purchase 50,000 shares of the Company's common stock at an exercise price of $26.77 per share. These options will vest in one-third annual increments beginning on the first anniversary of his date of employment. The grant, which was approved by the Company's compensation committee, was made under a standalone inducement stock option agreement, but on terms substantially the same as grants made under the Company's Amended and Restated 2004 Long Term Incentive Plan and related stock option agreement, pursuant to NASDAQ Marketplace Rule 5635(c)(4). This agreement includes provisions for full accelerated vesting of the options upon a change of control, or partial accelerated vesting in the event of termination without cause as defined in the agreement. The foregoing description is qualified by reference to the inducement stock option agreement, which is attached hereto as Exhibit 10.1, and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

10.1 Inducement Stock Option Agreement between Orthofix International N.V. and Kevin L. Unger, dated August 17, 2009

99.1 Press release, dated August 17, 2009

---